2023-01-04
A first patient in has been randomized in NANORAY-312, a global Phase 3 registration trial evaluating NBTXR3 (also known as PEP503) for the treatment of elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who are ineligible for platinum-based chemotherapy.
2023-01-03
